A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2002
10/29/2002	US6471959 Human transferase
10/29/2002	CA2291068C Method for the preparation of citalopram
10/25/2002	WO2001083451A1 Novel bicyclic compounds
10/25/2002	WO2001078652A2 Methods for drug discovery, disease treatment, and diagnosis using metabolomics
10/25/2002	CA2443806A1 Methods for drug discovery, disease treatment, and diagnosis using metabolomics
10/25/2002	CA2383175A1 Methods and kits for treating depression or preventing deterioration of cognitive function
10/24/2002	WO2002084297A1 Diagnostic and therapeutic use of a nuclear restricted protein for alzheimer's disease and related neurodegenerative disorders
10/24/2002	WO2002084249A2 Therapeutic and diagnostic uses of antibody specificity profiles
10/24/2002	WO2002083926A2 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	WO2002083898A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	WO2002083879A2 Immunotherapy based on dendritic cells
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083870A2 Pufa polyketide synthase systems and uses thereof
10/24/2002	WO2002083847A2 Cdna encoding the human alpha2 delta4 calcium channel subunit
10/24/2002	WO2002083841A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/24/2002	WO2002083733A2 Polynucleotides and polypeptides of the ifnalpha-6 gene
10/24/2002	WO2002083729A2 Polypeptides derived from amyloid precursor peptide (app) and their uses
10/24/2002	WO2002083716A2 Type b botulism toxin inhibitors
10/24/2002	WO2002083712A2 Transporters and ion channels
10/24/2002	WO2002083709A2 Kinases and phosphatases
10/24/2002	WO2002083684A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083683A1 Novel tricyclic pyridyl benzazepine carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083680A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083678A1 Tricyclic diazepines as tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083673A1 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
10/24/2002	WO2002083672A1 Antiviral pyrazolopyridine compounds
10/24/2002	WO2002083668A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	WO2002083667A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	WO2002083666A1 Substituted benzofuran-2-carboxamides derivatives
10/24/2002	WO2002083665A1 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083660A1 Remedies
10/24/2002	WO2002083656A2 5-membered heterocycles, preparation and use thereof as mao inhibitors and lipid peroxidation inhibitors, preparation thereof and use thereof as medicaments
10/24/2002	WO2002083655A1 Prodrugs of cox-2 inhibitors
10/24/2002	WO2002083652A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
10/24/2002	WO2002083651A2 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
10/24/2002	WO2002083648A1 Novel 1h-indazole compound
10/24/2002	WO2002083645A1 Novel compounds
10/24/2002	WO2002083643A1 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
10/24/2002	WO2002083642A1 Compounds useful as anti-inflammatory agents
10/24/2002	WO2002083640A1 Nicotinic acetylcholine receptor ligands
10/24/2002	WO2002083628A1 1,4-disubstituted benzo-fused compounds
10/24/2002	WO2002083627A2 Ligands des integrins avss6
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002	WO2002083182A2 The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
10/24/2002	WO2002083179A2 Fusion proteins
10/24/2002	WO2002083177A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
10/24/2002	WO2002083175A1 Visual function improving agents
10/24/2002	WO2002083166A1 Interferon-polymer complexes and medicinal use thereof
10/24/2002	WO2002083159A1 Palliative effects of morinda citrifolia oil and juice
10/24/2002	WO2002083158A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles
10/24/2002	WO2002083149A1 Drugs fo rpromoting the proliferation, differentiation and/or survival of glial cells containing cyclic phosphatidic acid
10/24/2002	WO2002083148A1 Nerve cell survival promoters containing cyclic phosphatidic acid derivative
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083135A2 Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
10/24/2002	WO2002083133A1 Novel oral general anesthetics and metabolitically resistant anticonvulsants
10/24/2002	WO2002083128A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
10/24/2002	WO2002083127A1 Protein modification-inhibitory compositions
10/24/2002	WO2002083122A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	WO2002083119A1 Pharmaceutical composition comprising ibuprofen and prochlorperazine
10/24/2002	WO2002083116A1 Methods of treating prion disease in mammals comprising administering a chaotropic agent such as guanidine, urea or potassium iodide
10/24/2002	WO2002083115A1 Treatment of disorders secondary to organic impairments
10/24/2002	WO2002083107A1 Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins
10/24/2002	WO2002083103A2 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	WO2002083083A2 Pharmaceutically active compounds and methods of use
10/24/2002	WO2002083071A2 Heterocyclic analgesic compounds and methods of use thereof
10/24/2002	WO2002083058A2 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers
10/24/2002	WO2002074763A9 Benzimidazol derivatives modulate chemokine receptors
10/24/2002	WO2002064557A3 New crystal forms of oxcarbazepine and processes for their preparation
10/24/2002	WO2002057253A3 Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders
10/24/2002	WO2002057226A9 68730 and 69112 protein kinase molecules and uses therefor
10/24/2002	WO2002055479A3 Esters of alkylcarboxy amino acids as prodrugs of modulators of the kainate receptor
10/24/2002	WO2002053140A3 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002050057A8 Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002040015A8 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
10/24/2002	WO2002036596A3 CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
10/24/2002	WO2002030897A3 Compositions and methods for regulating the nervous system
10/24/2002	WO2002026258A3 Treatment of immune-mediated diseases by oral administration of plasma fractions
10/24/2002	WO2002024659A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
10/24/2002	WO2002003972A3 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
10/24/2002	WO2002000913A9 MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2
10/24/2002	WO2002000210A3 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
10/24/2002	WO2001098265B1 Process for isolating enantiomers of racemic cetamine
10/24/2002	WO2001076568B1 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/24/2002	WO2001062793A9 Estrogen receptor beta variants and methods of detection thereof
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	WO2000040247A9 2-oxy-benzoxazinone derivatives for the treatment of obesity
10/24/2002	US20020156275 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
10/24/2002	US20020156264 And method of using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders
10/24/2002	US20020156254 Nucleotide sequences coding polypeptide for use in the treatment of stress, diabetes, cancer, inflammatory and cardiovascular disorders
10/24/2002	US20020156246 15625 receptor, a novel G-protein coupled receptor
10/24/2002	US20020156131 Intravenous valproate for acute treatment of migraine headache
10/24/2002	US20020156127 Carbamate compounds for use in the treatment of pain
10/24/2002	US20020156124 Paclitaxel, a solvent, a surfactant, a substituted cellulosic polymer, and a P-glycoprotein inhibitor; supersaturation of a microemulsion upon contact with water
10/24/2002	US20020156122 Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
10/24/2002	US20020156113 Farnesyl transferase inhibitors; anticancer agents

1 ... 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 ... 1833